Now Enrolling

advance
immune thrombocytopenia study

ADVANCE: A Phase 3 Clinical Study in Primary Immune Thrombocytopenia

ADVANCE is a Clinical Trial for the treatment of ITP

The ADVANCE study is designed to assess how effective and safe the investigational study drug (efgartigimod) is compared to a placebo as a possible treatment for adults living with primary ITP, primary being the absence of other causes or disorders associated with thrombocytopenia.

What we heard there is still an unmet need for…	How the study addresses these unmet needs
Treatment options for patients with diffcult to treat ITP	Patients included in the trials will have been exposed to at least 2 treatments for ITP
A therapy designed to target the underlying cause of ITP	Efgartigimod is thought to reduce the presence of antibodies that contribute to the low platelet count in ITP and has the potential to impact both destruction and production of the platelets
A treatment that provides a durable response with a strong safety profile and limited side effects	The study is designed to show the durability of a sustained platelet count response over the 24-week trial period. Additionally, the safety of efgartigimod and the incidence and severity of adverse events will be monitored and measured
A treatment that accounts for variation in patients' needs and response to treatment	Efgartigimod treatment frequency will be adjusted based on platelet count
The opportunity to continue to receive active drug following the trial	Patients who complete the 24-week trial period will have the opportunity to receive efgartigimod in a 1-year open label extension study if the appropriate criteria are met
Assistance with travel to clinical trial visits	Travel and logistical assistance, including transportation, lodging and meals associated with travel to and from the study site, may be provided with approval

Efgartigimod is an investigational agent that is currently being studied in multiple disease states. Efgartigimod is an investigational agent that is not currently approved for use by any regulatory agency as efficacy and safety have not been established.